STE · Q4 2026 Earnings

Narrative arc: Q1 FY2026 FX-funded raise, tariffs worsened → Q2 FY2026 organic-driven raise, conservatism cracking → Q3 FY2026 top of band off, AST visibility lost → Q4 FY2026 cautious into AST 1H, tariff narrative inverted.

The tariff narrative has fully inverted across four quarters — from $55M projected headwind to disclosed tailwind. Through FY2026 management walked the tariff drag up quarter by quarter while flagging mitigation work as the path to FY2027 offset. FY2026 incremental tariff impact ultimately came in at $46M (below the $55M figure carried through most of the year), with Q4 incremental tariffs landing at only ~$10M — Karen attributed the Q4 undershoot to lower volumes in materials and products sourced from outside the U.S. This quarter the figure is gone from the forward guide. Karen reframes: "in terms of tariffs, the recent changes are favorable to us and serve to offset the volume increase for next year. So in an odd twist, tariffs are an OK thing for us looking at 27." The four-quarter arc from quantified persistent headwind to disclosed-but-unquantified tailwind removes a hard datapoint investors had been using to test management discipline. Either the cushion has been rebuilt cleanly or the absorption is now hidden inside the muted EBIT margin expansion — both are possible, neither is verifiable.

AST has shifted from steady compounder to cautious-into-1H-comps — but is still the fastest segment in the FY2027 guide. Q3 management openly admitted they could not explain October weakness. This quarter Dan states: "We are taking a more conservative approach on our outlook to AST to start the year. Our MedTech customers continue to manage inventory levels carefully, and we are heading into the new year with some difficult comparisons in the first half, leaving us cautious." Importantly, AST is still guided to 7–8% CC organic in FY2027 — above the 6–7% guided for Healthcare and Life Sciences and above the 6–7% total-company guide. The caution is relative to AST's own historical pace and the difficult 1H comps, not absolute; if anything, Healthcare and Life Sciences at 6–7% are the larger contributors to total-company organic deceleration vs. FY2026's 7.3%. Q4 AST CC organic of just +1.6% — even with weather distortion — underscores the near-term deceleration that has management framing the 1H cautiously.

Adjusted EBIT margin expansion is being capped despite operational outperformance. FY2026 adjusted EBIT margin expanded 10bps to 23.3% despite ~$46M of incremental tariffs (an 80bps drag, per Dan). The FY2027 guide caps adjusted EBIT margin expansion at "approximately 50 basis points at the high end" off that 23.3% base — i.e., the low end of the guide implies flat to negative margin expansion in a year with ~200bps of pricing flowing in. Dan's framing: "We will be making select investments in FY27, driving incremental operating expenses, including kicking off a multi-year project to support our service workflows with upgraded technologies utilizing AI." The pricing power is being redeployed into a multi-year tech build rather than dropped to the line.

Capital returns are now structurally throttled by tax structure, not opportunity. The CFO's explanation of the buyback cadence: "Because of the withholding tax, we believe a measured approach is the right answer. We have this incremental hurdle when we do buybacks to overcome. So when we model the withholding tax, the lost interest, potentially having to borrow to go bigger, it starts to not make sense." This is a structural disclosure: the $1B authorization is real but the friction on deploying it is non-operational and not improving. The framed cadence is $200–300M per year. Combined with the M&A "kissed a lot of frogs" framing from Q3, the balance sheet capacity is now visibly idle by design.